Bioinfra 추진 7 billion KRW Fundraising to Secure Growth Engine

[Asia Economy Reporter Hyunseok Yoo] Bioinfra Life Sciences, a company specializing in early cancer diagnosis based on protein biomarkers, announced on the 18th that it plans to raise a total of 7 billion KRW by next month through the issuance of Convertible Preferred Shares (CPS) for research and development purposes.

3 billion KRW will be raised by the end of this month from two institutions (Korea Investment Partners and Skywalk Asset Management). The remaining 4 billion KRW is planned to be secured through two venture capital firms by June. Currently, financial due diligence and investment reviews are underway.

Bioinfra plans to use the 7 billion KRW to be raised by next month to promote the approval of I-Finder, invest in R&D, and strengthen sales capabilities. Based on these achievements, the company aims to successfully complete its transfer listing to KOSDAQ next year.

The i-FINDER®LC, scheduled for release as an auxiliary diagnostic tool for lung cancer, shows high sensitivity and specificity. Exploratory clinical trials were completed last year, and confirmatory clinical trials are currently underway. The company also plans to enter new markets thereafter.

Additionally, X-FINDER®BC, designed as an auxiliary diagnostic tool for breast cancer, had a paper published last year in an SCIE international journal. Exploratory clinical trials are planned for the second half of this year, with the goal of obtaining approval from the Ministry of Food and Drug Safety by the second half of next year.

Furthermore, to expand its sales pipeline, the company launched an ultrasound beauty device and cosmetics (SONOCUBE) at the end of last year, receiving positive consumer responses. The blood multi-marker M-FINDER®HCC for monitoring high-risk liver cancer patients is also planned to undergo clinical trials in the second half of this year, aiming for commercialization.

CEO Deokyun Lee stated, “The investment we are securing this time is significant in that it recognizes Bioinfra’s high growth potential from professional investment institutions and allows us to focus all our capabilities on continuous and stable technology development and strengthening sales capabilities even after the transfer listing to the KOSDAQ market.” He added, “We will further enhance shareholder value and successfully complete the transfer listing to the KOSDAQ market without any setbacks.”